MDGL
Madrigal Pharmaceuticals Inc.
$444.72
+$4.65(+1.06%)
27
Overall
--
Value
27
Tech
--
Quality
Market Cap
$9.81B
Volume
184.18K
52W Range
$200.63 - $457.16
Target Price
$474.13
Order:
Income Statement
| Metric | Trend | Chart | 2015 Dec | 2016 Dec | 2017 Dec | 2018 Dec | 2019 Dec | 2020 Dec | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| REVENUE | ||||||||||||
| Total Revenue | -- | -- | -- | -- | -- | -- | -- | -- | -- | $180.1M | ||
| Total Revenue | -- | -- | -- | -- | -- | -- | -- | -- | -- | $180.1M | ||
| COST OF GOODS SOLD | ||||||||||||
| Cost of Revenue | -- | -- | -- | -- | -- | -- | -- | -- | -- | $6.2M | ||
| GROSS PROFIT | ||||||||||||
| Gross Profit | -- | -- | -- | -- | -- | -- | -- | -- | -- | $173.9M | ||
| OPERATING EXPENSES | ||||||||||||
| Operating Expenses | $-3.2M | $-25.2M | $-32.1M | $40.7M | $95.0M | $206.7M | $242.5M | $293.6M | $380.5M | $671.8M | ||
| Research & Development | $2.4M | $15.9M | $24.4M | $25.4M | $72.3M | $184.8M | $205.2M | $245.4M | $272.4M | $236.7M | ||
| Research Expense | $2.4M | $15.9M | $24.4M | $25.4M | $72.3M | $184.8M | $205.2M | $245.4M | $272.4M | $236.7M | ||
| Selling, General & Administrative | $805.8K | $9.3M | $7.7M | $15.3M | $22.6M | $21.9M | $37.3M | $48.1M | $108.1M | $435.1M | ||
| General & Administrative Expenses | $805.8K | $9.3M | $7.7M | $15.3M | $22.6M | $21.9M | $37.3M | $48.1M | $108.1M | $435.1M | ||
| Salaries & Wages | $-4.3M | $-7.9M | $-3.3M | $-13.5M | -- | -- | -- | $31.6M | $49.7M | $79.9M | ||
| Depreciation & Amortization | $-662.0K | -- | -- | -- | -- | -- | -- | -- | -- | -- | ||
| Depreciation & Amortization | $-662.0K | -- | -- | -- | -- | -- | -- | -- | -- | -- | ||
| Other Operating Expenses | $-67.6M | -- | $-32.1M | $-40.7M | $95.0M | $206.7M | $242.5M | $293.6M | $1.1M | $900.0K | ||
| OPERATING INCOME | ||||||||||||
| Operating income | $-3.2M | $-25.2M | $-32.1M | $-40.7M | $-95.0M | $-206.7M | $-242.5M | $-293.6M | $-380.5M | $-497.9M | ||
| EBITDA | $-3.2M | $-25.2M | $-31.1M | $-32.7M | $-83.8M | $-206.2M | $-241.4M | $-290.1M | $-386.9M | $-459.6M | ||
| NON-OPERATING ITEMS | ||||||||||||
| Interest Expense (Non-Operating) | $3.6M | $1.2M | -- | -- | -- | -- | -- | $4.0M | $12.7M | $22.4M | ||
| Interest Income Operating | -- | -- | $216.0K | $3.0M | -- | -- | -- | -- | -- | -- | ||
| Intinc | $-1.1M | $48.0K | $558.0K | $7.7M | $11.0M | $4.3M | $363.0K | $2.2M | $19.6M | $46.7M | ||
| Net Non-Operating Interest Income/Expense | $-3.6M | $-1.2M | $558.0K | $7.7M | $11.0M | $4.3M | $363.0K | $-1.8M | $19.6M | $46.7M | ||
| Other Income/Expense | -- | -- | $-350.0K | $-200.0K | $-765.0K | $-100.0K | $-273.0K | -- | -- | -- | ||
| Other Special Charges | -- | -- | $350.0K | $200.0K | $765.0K | $100.0K | $273.0K | -- | -- | -- | ||
| PRE-TAX INCOME | ||||||||||||
| EBIT | $-3.2M | $-25.2M | $-31.2M | $-32.8M | $-83.9M | $-206.7M | $-241.8M | $-291.4M | $-389.9M | $-462.8M | ||
| Pre-Tax Income | $-6.8M | $-26.4M | $-31.2M | $-32.8M | $-83.9M | $-202.2M | $-241.8M | $-295.4M | $-360.9M | $-465.9M | ||
| INCOME TAX | ||||||||||||
| Tax Provision | $309.0K | $-29.0K | $-9.3M | $5.5M | $-6.6M | $-16.6M | $-19.6M | -- | $-16.2M | $-19.3M | ||
| NET INCOME | ||||||||||||
| Net Income | $-6.8M | $-26.4M | $-31.2M | $-32.8M | $-83.9M | $-202.2M | $-241.8M | $-295.4M | $-373.6M | $-465.9M | ||
| Net Income (Continuing Operations) | $-6.8M | $-26.4M | $-31.2M | $-32.8M | $-83.9M | $-202.2M | $-241.8M | $-295.4M | $-373.6M | $-465.9M | ||
| Net Income (Discontinued Operations) | $-6.8M | $-26.4M | $-31.2M | $-32.8M | $-83.9M | $-202.2M | $-241.8M | $-295.4M | $-373.6M | $-465.9M | ||
| Net Income (Common Stockholders) | $-6.8M | $-26.4M | $-31.2M | $-32.8M | $-83.9M | $-202.2M | $-241.8M | $-295.4M | $-360.9M | $-465.9M | ||
| Normalized Income | -- | -- | -- | -- | -- | -- | -- | -- | -- | $-470.5M | ||
| TOTALS | ||||||||||||
| Total Expenses | $-3.2M | $-25.2M | $-32.1M | $40.7M | $95.0M | $206.7M | $242.5M | $293.6M | $380.5M | $678.0M | ||
| SHARE & EPS DATA | ||||||||||||
| Average Shares Outstanding | $3.7M | $5.2M | $12.2M | $14.8M | $15.4M | $15.4M | $16.5M | $17.1M | $18.7M | $21.3M | ||
| Average Shares Outstanding (Diluted) | $3.7M | $5.2M | $12.3M | $14.8M | $15.4M | $15.4M | -- | $17.1M | $18.7M | $21.3M | ||
| Shares Outstanding | $3.9M | $12.2M | $14.2M | $15.4M | $15.4M | $16.0M | $17.1M | $18.1M | $19.9M | $22.1M | ||
| Basic EPS | -- | -- | -- | -- | $-5.45 | $-13.09 | $-14.63 | $-17.23 | $-19.99 | $-21.9 | ||
| Basic EPS (Continuing Operations) | -- | -- | -- | -- | $-5.45 | $-13.09 | $-14.63 | $-17.23 | $-19.99 | $-21.9 | ||
| Diluted EPS | $-18.55 | $-5.07 | $-2.54 | $-2.22 | $-5.45 | $-13.09 | $-14.63 | $-17.23 | $-19.99 | $-21.9 | ||
| Diluted EPS (Continuing Operations) | -- | -- | -- | $-2.22 | -- | -- | -- | $-17.23 | $-19.99 | $-21.9 | ||
| OTHER METRICS | ||||||||||||
| Interest Expense Operating | -- | -- | -- | -- | -- | -- | -- | -- | $24.6M | -- | ||
| Other Gand A | $805.8K | $9.3M | $7.7M | $15.3M | $22.6M | $21.9M | $37.3M | $48.1M | $108.1M | $435.1M | ||
| Rent And Landing Fees | $805.8K | $9.3M | $7.7M | $-239.0K | $239.0K | -- | -- | -- | -- | -- | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | MDGL | $444.72 | +1.1% | 184.18K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Madrigal Pharmaceuticals Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW